Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sustained release intravitreal dexamethasone

D P Hainsworth1, P A Pearson, J D Conklin

  • 1Department of Ophthalmology, University of Kentucky, Lexington, USA.

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A cryogenic continuously rotating half-wave plate mechanism for the POLARBEAR-2b cosmic microwave background receiver.

The Review of scientific instruments·2020
Same author

A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients.

Bone marrow transplantation·2017
Same author

Association between use of proton pump inhibitors and non-typhoidal salmonellosis identified following investigation into an outbreak of Salmonella Mikawasima in the UK, 2013.

Epidemiology and infection·2015
Same author

Morphine pharmacokinetics following intra-articular administration of a novel sustained release opioid (CDS-PM-101) for the relief of post-operative orthopaedic pain.

Journal of controlled release : official journal of the Controlled Release Society·2005
Same author

Correlation of in vitro-in vivo release rates for sustained release nevirapine implants in rats.

Journal of controlled release : official journal of the Controlled Release Society·2005
Same author

An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy.

The British journal of ophthalmology·2004
Same journal

Not All that Clouds Is Infection: Intravitreal Precipitation after Sequential Antibiotic Injection.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

Physicochemical Fingerprinting of Cyclosporine A Ophthalmic Emulsions as a New Approach Methodology for Clinical Tolerability.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

Exploring the Role of the Zeis Gland in Dry Eye Disease Associated with Demodex Blepharitis.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

Eyes on New Product Development-Number 134.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
Same journal

Integrated Bioinformatics and Explainable Machine Learning Analyses Reveal Mesenchymal Stem Cell Exosome-Related Biomarkers for Diabetic Retinopathy.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics·2026
See all related articles

A novel intravitreal implant delivers sustained dexamethasone for treating proliferative vitreoretinopathy (PVR). This biocompatible device maintained therapeutic drug levels for over three months with no observed toxicity.

Area of Science:

  • Ophthalmology
  • Biomaterials Science
  • Pharmacology

Background:

  • Proliferative vitreoretinopathy (PVR) poses a significant challenge in retinal surgery.
  • Sustained intraocular drug delivery is crucial for managing complex ocular conditions like PVR.
  • Dexamethasone has shown potential therapeutic benefits for PVR.

Purpose of the Study:

  • To develop and evaluate an implantable system for sustained intravitreal dexamethasone release.
  • To assess the in vitro and in vivo release kinetics of the dexamethasone implant.
  • To determine the safety and efficacy of the implant in a preclinical model.

Main Methods:

  • Dexamethasone pellets were coated with biocompatible, nonerodible polymers.
  • In vitro release rates were measured.

Related Experiment Videos

  • Implants were tested in rabbit vitreous for in vivo release, concentration, and toxicity via histopathology and electroretinography.

    • Main Results:

    • The implants demonstrated sustained dexamethasone release of approximately 1 ug/hr in vitro and 1.5 ug/hr in vivo.
    • Intravitreal concentrations of 2.5 +/- 1.2 ug/hr were maintained for over 3 months post-implantation.
    • Histopathological and electrographic evaluations showed no evidence of inflammation or retinal abnormalities, indicating good biocompatibility.

    Conclusions:

    • The developed implantable system provides sustained intravitreal dexamethasone delivery.
    • This system maintains therapeutic drug levels for extended periods.
    • The implant is well-tolerated and shows no significant toxicity, suggesting its potential for PVR treatment.